ARQT — Arcutis Biotherapeutics, Inc.

Summary of Arcutis Biotherapeutics Inc. Q2 2026 Earnings Call

1. Key Financial Results and Metrics

• Net Product Revenues: $129.9 million, a 59% increase year-over-year and a 23% increase from Q1 2026.
• Gross to Net Rate: Remained stable in the 50s, with expectations to moderate to the low 50s by year-end.
• Net Income: $15 million, compared to a net loss of $15.9 million in Q2 2025.
• Cash and Marketable Securities: $238.9 million, with positive cash flow from operating activities of $12.6 million.
• Debt: Total debt stands at $101.9 million.
• Revised Revenue Guidance: Increased full-year 2026 guidance from $480-$495 million to $525-$540 million.

2. Strategic Updates and Business Highlights

• ZORYVE Growth: Continued expansion in the dermatology market, with significant demand for ZORYVE, particularly after receiving FDA approval for use in children as young as 2 for plaque psoriasis.
• New Indications: FDA accepted a supplemental NDA for ZORYVE 0.05% for atopic dermatitis in infants aged 3 months, with a PDUFA date of February 23, 2027.
• Patient Access Initiatives: Launch of a virtual health platform and partnership with an AI-enabled prescription workflow tool to enhance patient access and streamline the prescription process.
• Sales Force Expansion: Completion of the dermatology sales force expansion, with plans to engage primary care and pediatric providers by the end of July 2026.

3. Forward Guidance and Outlook

• Sales Growth Expectations: Anticipation of continued quarter-over-quarter growth in net sales driven by sustained demand for ZORYVE and the impact of new commercial initiatives.
• Investment in Innovation: Plans to reinvest cash flow into the business to drive growth and expand the pipeline, with a focus on new indications and patient access strategies.

4. Bad News, Challenges, or Points of Concern

• Leadership Transition: Resignation of Chief Commercial Officer Todd Edwards, with Rob Lisicki stepping in as interim CCO. Concerns about maintaining momentum during this transition.
• Market Competition: The dermatology space is competitive, with ongoing pressures from other topical therapies and the need to differentiate ZORYVE effectively.
• Regulatory Risks: Potential delays or challenges in the approval process for new indications could impact growth projections.

5. Notable Q&A Insights

• Growth Drivers: Management indicated that growth in the second half of 2026 will primarily come from increased prescriptions and the impact of new initiatives rather than significant improvements in gross-to-net metrics.
• Telehealth Opportunities: The telehealth platform is expected to broaden patient access, particularly for those unable to see dermatologists in person, with a focus on converting patients who may have previously used topical steroids.
• Enrollment in Clinical Trials: Positive enrollment trends in ongoing clinical trials, particularly for the vitiligo study, which is fully enrolled, indicating strong interest in ZORYVE's potential applications.
• Market Share: ZORYVE holds nearly 50% market share in the branded topical non-steroidal class, with expectations for continued growth as healthcare providers shift away from topical steroids.

This summary encapsulates the key points from the earnings call, highlighting Arcutis' strong financial performance, strategic initiatives, and outlook while acknowledging potential challenges and competitive pressures in the market.